Comprehensive medication guide to Lybalvi including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
With commercial insurance and the LYBALVI Co-Pay Savings Card, eligible patients ages 18–64 may pay $0 for the first 3 fills; thereafter as little as $20 per 30-day supply (maximum savings of $450 per fill). Medicare Part D and Medicaid cover Lybalvi with prior authorization; copay varies by plan and coverage tier.
Estimated Cash Pricing
Lybalvi costs approximately $1,673–$2,063 per 30-day supply at retail pharmacies without insurance (list price/WAC is $1,729.54 as of January 2026). GoodRx coupons can reduce the price to approximately $1,673 for a 30-day supply. No generic is available.
Medfinder Findability Score
65/100
Summarize with AI
On this page
Lybalvi (olanzapine/samidorphan) is a prescription oral tablet that combines two active ingredients: olanzapine, an atypical antipsychotic, and samidorphan, a mixed opioid antagonist/partial agonist. It was developed by Alkermes, Inc. and received FDA approval on May 28, 2021. Lybalvi is taken once daily, with or without food.
Lybalvi is FDA-approved for two conditions in adults: schizophrenia, and bipolar I disorder (for acute treatment of manic or mixed episodes as monotherapy or as an adjunct to lithium or valproate, and as maintenance monotherapy). It is not approved for bipolar depression, dementia-related psychosis, or use in children.
The key innovation of Lybalvi over standard olanzapine is its weight management profile. Olanzapine is one of the most effective antipsychotics but is notorious for causing significant weight gain. Samidorphan was added to counteract this by blocking mu-opioid receptors that regulate appetite. Clinical trials demonstrated significantly less weight gain with Lybalvi compared to olanzapine alone.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Lybalvi works through two complementary mechanisms. Olanzapine, the antipsychotic component, blocks dopamine receptors (D1–D4) and serotonin receptors (5-HT2A) in the brain. This receptor blockade reduces the overactive dopamine signaling associated with hallucinations, delusions, and disorganized thinking in schizophrenia, and stabilizes the extreme mood changes in bipolar I disorder.
Samidorphan, the opioid antagonist component, blocks mu-opioid receptors in the brain and gut. This blockade is thought to interfere with the appetite-stimulating and reward circuits that olanzapine dysregulates — reducing the excessive hunger and metabolic disruption that would otherwise lead to significant weight gain.
Because samidorphan actively occupies opioid receptors, Lybalvi is contraindicated in patients currently using opioids (including pain medications, buprenorphine, and methadone). Taking opioids with Lybalvi can precipitate severe withdrawal or, if the blockade is overridden with large opioid doses, lead to life-threatening respiratory arrest.
5 mg/10 mg — tablet
Starting strength; lowest available dose of the olanzapine component
10 mg/10 mg — tablet
Standard starting and maintenance dose for most patients
15 mg/10 mg — tablet
Mid-range maintenance dose
20 mg/10 mg — tablet
Maximum recommended dose
Lybalvi is not listed on the FDA's official drug shortage database as of 2026. However, patients commonly report difficulty filling their prescriptions due to several structural barriers. Lybalvi is a brand-only medication with no generic available — the only manufacturer is Alkermes, Inc. Its high wholesale cost (~$1,730/month) means many chain pharmacies don't stock it routinely.
The biggest real-world access barrier is insurance prior authorization. Most commercial plans, Medicare Part D, and Medicaid programs require PA before covering Lybalvi. Some plans also require step therapy — patients must document failure on other antipsychotics first. The PA process typically takes 3–14 business days and must be renewed annually.
If you're having trouble filling your Lybalvi prescription, medfinder can help. Enter your medication, dosage, and location and medfinder will contact pharmacies near you to identify which ones can fill your prescription, sending results directly to your phone.
Lybalvi is not a controlled substance, which means any licensed healthcare provider with a valid DEA registration can prescribe it without the special restrictions that apply to Schedule II-V medications. There are no quantity limits specific to Lybalvi, no mandatory in-person evaluation requirements, and no DEA schedule-based barriers to telehealth prescribing.
Psychiatrists — primary prescribers; specialists in schizophrenia and bipolar disorder management
Primary care physicians (PCPs) and family medicine doctors — often manage stable patients on ongoing antipsychotic therapy
Nurse practitioners (NPs) and physician assistants (PAs) — particularly those in psychiatric or mental health settings
Neurologists — occasionally prescribe for psychiatric comorbidities
Telehealth availability: Because Lybalvi is not a controlled substance, it can be prescribed via telepsychiatry platforms (Talkiatry, Teladoc, MDLive, Brightside Health, and others) without special DEA registration requirements. Telepsychiatry is a valuable option for patients with limited access to in-person psychiatric care.
No. Lybalvi (olanzapine/samidorphan) is not classified as a controlled substance by the DEA. It is not listed under any DEA schedule (Schedule I–V). This means Lybalvi can be prescribed by any licensed healthcare provider without the special restrictions that apply to controlled medications — no limited prescription quantities, no mandatory in-person evaluation requirements specific to controlled substances, and no DEA registration requirements for telehealth prescribing.
However, Lybalvi does contain samidorphan, an opioid antagonist, which creates unique drug interaction risks with opioid medications. While not a controlled substance itself, Lybalvi is contraindicated with opioids and can cause false positive drug tests for opioids on certain immunoassay screens. Patients should inform all healthcare providers and drug testers that they take Lybalvi.
Weight gain (19–25% of patients in clinical trials; significantly less than olanzapine alone)
Somnolence (drowsiness/sleepiness)
Dry mouth
Headache
Anxiety or restlessness
Insomnia
Nausea
Orthostatic hypotension (dizziness when standing; rate ~3.7% vs 0.4% with olanzapine alone)
Opioid withdrawal — if started in an opioid-dependent patient without required opioid-free interval
Life-threatening opioid intoxication — if patient tries to override opioid blockade with high opioid doses
Neuroleptic malignant syndrome (NMS) — rare, life-threatening (fever, muscle rigidity, confusion, autonomic instability)
DRESS syndrome — severe drug reaction (rash, fever, lymphadenopathy, organ involvement)
Metabolic changes — hyperglycemia/diabetes, dyslipidemia; requires monitoring
Tardive dyskinesia — involuntary repetitive movements; may be irreversible
Increased mortality in elderly patients with dementia-related psychosis — boxed warning; Lybalvi not approved for this population
Know what you need? Skip the search.
Olanzapine (Zyprexa)
Same antipsychotic component as Lybalvi but without samidorphan; causes significantly more weight gain. Generic available at ~$20–$50/month — much lower cost.
Quetiapine (Seroquel)
Atypical antipsychotic for schizophrenia and bipolar disorder (including depression). Generic available at ~$20–$60/month. More sedating; moderate metabolic effects.
Aripiprazole (Abilify)
Atypical antipsychotic with partial dopamine agonist mechanism; lowest metabolic and weight-gain risk among available generics. Generic at ~$15–$40/month.
Lurasidone (Latuda)
Atypical antipsychotic for schizophrenia and bipolar depression. Favorable weight profile. Must be taken with ≥350 calories. Generic now available.
Cariprazine (Vraylar)
Newer atypical antipsychotic for schizophrenia and full bipolar spectrum (mania, mixed, depression). Weight-neutral. Brand-only; high cost.
Prefer Lybalvi? We can find it.
Opioids (all types)
majorContraindicated. Lybalvi's samidorphan blocks opioid receptors. Co-administration can precipitate severe opioid withdrawal or, if blockade is overridden, life-threatening respiratory arrest. 7-day opioid-free interval required (short-acting); 14-day interval (long-acting) before starting.
Benzodiazepines (diazepam, lorazepam, alprazolam)
majorAdditive CNS depression and hypotension. Use with caution; monitor blood pressure and sedation levels.
Alcohol
majorSignificantly increased CNS depression and coordination impairment. Avoid alcohol during Lybalvi treatment.
Fluvoxamine (Luvox)
moderateCYP1A2 inhibitor that significantly increases olanzapine blood levels, raising side effect risk. Dose reduction of Lybalvi may be needed.
Carbamazepine (Tegretol)
moderateCYP1A2 inducer that reduces olanzapine levels by up to 50%, potentially reducing efficacy. Monitor clinical response.
Antihypertensives
moderateAdditive hypotension risk. Monitor blood pressure; may need to reduce antihypertensive dose.
Anticholinergic medications
moderateAdditive antimuscarinic effects including urinary retention, constipation, blurred vision, and confusion.
Tobacco smoking
moderateCYP1A2 induction from smoking reduces olanzapine levels by ~40%. Starting or stopping smoking requires prescriber notification and possible dose adjustment.
Lybalvi represents a meaningful clinical advance in antipsychotic therapy — bringing olanzapine's proven efficacy paired with meaningfully reduced weight gain risk. For patients who need olanzapine's power but face metabolic concerns, Lybalvi offers a compelling alternative to standard olanzapine monotherapy. Four-year extension data presented at APA 2024 confirms durable symptom control and metabolic stability over the long term.
The main practical challenges are cost (~$1,730/month list price) and insurance prior authorization requirements. However, the Co-Pay Savings Card, Patient Assistance Program, and ASPN Pharmacies support network provide meaningful pathways to access for most patient populations. Patients should always start the refill process at least two weeks before running out, and should connect with ASPN Pharmacies (855-820-9624) for help navigating insurance and pharmacy logistics.
If you're having difficulty locating Lybalvi at a pharmacy near you, medfinder can help. Simply enter your medication, dosage, and location and medfinder will contact pharmacies near you and send you results by text — saving you the time and frustration of calling pharmacies yourself.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini